UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 321 Summer Street, Suite 400 B ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) 321 Summer Street, Suite 400 Boston, Massachusetts 02210 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39397 INOZYME PHARMA, INC. (Exact ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ı | | | | | | | Our Mission | | | | | | | Fulfill an unmet medical need with therapeutic breakthroughs in rare diseases of pathologic mineralization and intimal proliferation | | | | | | December 2022 Legal Di ...

| --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ı | | | | | | Our Mission | | | | | | Fulfill an unmet medical need with therapeutic breakthroughs in diseases of abnormal mineralization | | | | | May 2022 Legal Disclaimer This presentation and any statements made orally during this presentation also contain estimat ...

| --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ı | | | | | | Our Mission | | | | | | Fulfill an unmet medical need with therapeutic breakthroughs in diseases of abnormal mineralization | | | | | April 2022 Legal Disclaimer This presentation and any statements made orally during this presentation also contain estimates and oth ...

OUR MISSION: Fulfill an unmet medical need with therapeutic breakthroughs in diseases of abnormal mineralization December 2020 Legal Disclaimer This presentation and any statements made orally during this presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, ...